Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-31true2023-01-01truetruetruetruetruefalse94falseNo description of principal activity115truefalse 03783386 2023-01-01 2023-12-31 03783386 2022-01-01 2022-12-31 03783386 2023-12-31 03783386 2022-12-31 03783386 2022-01-01 03783386 1 2023-01-01 2023-12-31 03783386 1 2022-01-01 2022-12-31 03783386 2 2022-01-01 2022-12-31 03783386 5 2023-01-01 2023-12-31 03783386 5 2022-01-01 2022-12-31 03783386 1 2023-01-01 2023-12-31 03783386 d:Exceptional 2023-01-01 2023-12-31 03783386 d:Exceptional 2022-01-01 2022-12-31 03783386 e:CompanySecretary1 2023-01-01 2023-12-31 03783386 e:Director1 2023-01-01 2023-12-31 03783386 e:Director1 2023-12-31 03783386 e:Director2 2023-01-01 2023-12-31 03783386 e:Director2 2023-12-31 03783386 e:Director3 2023-01-01 2023-12-31 03783386 e:Director4 2023-01-01 2023-12-31 03783386 e:Director5 2023-01-01 2023-12-31 03783386 e:Director5 2023-12-31 03783386 e:Director6 2023-01-01 2023-12-31 03783386 e:Director6 2023-12-31 03783386 e:Director7 2023-01-01 2023-12-31 03783386 e:Director7 2023-12-31 03783386 e:Director8 2023-01-01 2023-12-31 03783386 e:Director8 2023-12-31 03783386 e:RegisteredOffice 2023-01-01 2023-12-31 03783386 d:Buildings d:LongLeaseholdAssets 2023-01-01 2023-12-31 03783386 d:Buildings d:LongLeaseholdAssets 2023-12-31 03783386 d:Buildings d:LongLeaseholdAssets 2022-12-31 03783386 d:PlantMachinery 2023-01-01 2023-12-31 03783386 d:PlantMachinery 2023-12-31 03783386 d:PlantMachinery 2022-12-31 03783386 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 03783386 d:FurnitureFittings 2023-01-01 2023-12-31 03783386 d:FurnitureFittings 2023-12-31 03783386 d:FurnitureFittings 2022-12-31 03783386 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 03783386 d:OfficeEquipment 2023-01-01 2023-12-31 03783386 d:OfficeEquipment 2023-12-31 03783386 d:OfficeEquipment 2022-12-31 03783386 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 03783386 d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 03783386 d:CurrentFinancialInstruments 2023-12-31 03783386 d:CurrentFinancialInstruments 2022-12-31 03783386 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 03783386 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 03783386 f:UnitedKingdom 2023-01-01 2023-12-31 03783386 f:UnitedKingdom 2022-01-01 2022-12-31 03783386 f:RestEuropeOutsideUK 2023-01-01 2023-12-31 03783386 f:RestEuropeOutsideUK 2022-01-01 2022-12-31 03783386 f:RestWorldOutsideUK 2023-01-01 2023-12-31 03783386 f:RestWorldOutsideUK 2022-01-01 2022-12-31 03783386 d:UKTax 2023-01-01 2023-12-31 03783386 d:UKTax 2022-01-01 2022-12-31 03783386 d:ShareCapital 2023-01-01 2023-12-31 03783386 d:ShareCapital 2023-12-31 03783386 d:ShareCapital 2022-01-01 2022-12-31 03783386 d:ShareCapital 2022-12-31 03783386 d:ShareCapital 2022-01-01 03783386 d:SharePremium 2023-01-01 2023-12-31 03783386 d:SharePremium 2023-12-31 03783386 d:SharePremium 1 2023-01-01 2023-12-31 03783386 d:SharePremium 2022-01-01 2022-12-31 03783386 d:SharePremium 2022-12-31 03783386 d:SharePremium 2022-01-01 03783386 d:SharePremium 1 2022-01-01 2022-12-31 03783386 d:SharePremium 2 2022-01-01 2022-12-31 03783386 d:CapitalRedemptionReserve 2023-01-01 2023-12-31 03783386 d:CapitalRedemptionReserve 2023-12-31 03783386 d:CapitalRedemptionReserve 1 2023-01-01 2023-12-31 03783386 d:CapitalRedemptionReserve 2022-01-01 2022-12-31 03783386 d:CapitalRedemptionReserve 2022-12-31 03783386 d:CapitalRedemptionReserve 2022-01-01 03783386 d:CapitalRedemptionReserve 2 2022-01-01 2022-12-31 03783386 d:RevaluationReserve 1 2022-01-01 2022-12-31 03783386 d:OtherMiscellaneousReserve 2023-01-01 2023-12-31 03783386 d:OtherMiscellaneousReserve 2023-12-31 03783386 d:OtherMiscellaneousReserve 1 2023-01-01 2023-12-31 03783386 d:OtherMiscellaneousReserve 2022-01-01 2022-12-31 03783386 d:OtherMiscellaneousReserve 2022-12-31 03783386 d:OtherMiscellaneousReserve 2022-01-01 03783386 d:OtherMiscellaneousReserve 1 2022-01-01 2022-12-31 03783386 d:OtherMiscellaneousReserve 2 2022-01-01 2022-12-31 03783386 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 03783386 d:RetainedEarningsAccumulatedLosses 2023-12-31 03783386 d:RetainedEarningsAccumulatedLosses 1 2023-01-01 2023-12-31 03783386 d:RetainedEarningsAccumulatedLosses 2022-01-01 2022-12-31 03783386 d:RetainedEarningsAccumulatedLosses 2022-12-31 03783386 d:RetainedEarningsAccumulatedLosses 2022-01-01 03783386 d:RetainedEarningsAccumulatedLosses 1 2022-01-01 2022-12-31 03783386 d:RetainedEarningsAccumulatedLosses 2 2022-01-01 2022-12-31 03783386 e:OrdinaryShareClass1 2023-01-01 2023-12-31 03783386 e:OrdinaryShareClass1 2023-12-31 03783386 e:OrdinaryShareClass1 2022-12-31 03783386 e:OrdinaryShareClass2 2023-01-01 2023-12-31 03783386 e:OrdinaryShareClass2 2023-12-31 03783386 e:OrdinaryShareClass2 2022-12-31 03783386 e:OrdinaryShareClass3 2023-01-01 2023-12-31 03783386 e:OrdinaryShareClass3 2023-12-31 03783386 e:OrdinaryShareClass3 2022-12-31 03783386 e:FRS102 2023-01-01 2023-12-31 03783386 e:Audited 2023-01-01 2023-12-31 03783386 e:FullAccounts 2023-01-01 2023-12-31 03783386 e:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 03783386 d:Subsidiary1 2023-01-01 2023-12-31 03783386 d:Subsidiary1 1 2023-01-01 2023-12-31 03783386 d:WithinOneYear 2023-12-31 03783386 d:WithinOneYear 2022-12-31 03783386 d:BetweenOneFiveYears 2023-12-31 03783386 d:BetweenOneFiveYears 2022-12-31 03783386 d:MoreThanFiveYears 2023-12-31 03783386 d:MoreThanFiveYears 2022-12-31 03783386 2 2023-01-01 2023-12-31 03783386 4 2023-01-01 2023-12-31 03783386 6 2023-01-01 2023-12-31 03783386 g:PoundSterling 2023-01-01 2023-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 03783386










MEDPHARM LIMITED










ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

 
MEDPHARM LIMITED
 
 
COMPANY INFORMATION


Directors
M B Brown (resigned 17 January 2024)
A G Muddle (resigned 17 January 2024)
D J Parker 
T Wahlbrink 
E F Ciolfi (resigned 31 March 2023)
P D Walsh (appointed 31 October 2024)
M Kane (appointed 27 June 2024, resigned 31 October 2024)
E Hjerpe (appointed 27 June 2024)




Company secretary
P D Walsh



Registered number
03783386



Registered office
Unit 3, Chancellor Court 50 Occam Road
Surrey Research Park

Guildford

Surrey

GU2 7AB




Independent auditor
MHA

6th Floor

2 London Wall Place

London

EC2Y 5AU





 
MEDPHARM LIMITED
 

CONTENTS



Page
Strategic report
 
1 - 3
Directors' report
 
4 - 6
Independent auditor's report
 
7 - 10
Statement of comprehensive income
 
11
Statement of financial position
 
12
Statement of changes in equity
 
13 - 14
Notes to the financial statements
 
15 - 30


 
MEDPHARM LIMITED
 
 
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

Introduction
 
The directors present the Strategic Report for the year ended 31 December 2023.
Medpharm Limited is a leading, global provider of contract topical and transdermal product design and formulation development services.
Medpharm has fully established R&D centres in the US and UK and GMP clinical manufacturing in the US and UK. Since establishment in 1999, Medpharm has partnered with a variety of high profile clients to develop and deliver over 30 superior products to the market which are directly are directly benefiting patients with a wide variety of conditions.
Medpharm are experts at reducing risk and accelerating development times for generic and proprietary
pharmaceutical customers through proprietary, industry-leading performance-testing models. Well established
as a global leader in dermatology, nail, mucosal membrane and transdermal product development, Medpharm
also offers innovative solutions for opthalmic and airway preparations. These solutions are recognised for their
scientific rigour by regulators and investors.
Medpharm also holds patented technology based on the 'patch-in-a-can' concept - "MedSpray". MedSpray benefits patients by offering the possibility of long-term dosing of a product through the skin or mucosal membrane from a clear 'patch' conveniently applied as a spray from a can. It is applicable to a wide variety of products including those for curing infections or pain management. The unique dosing offers clients the opportunity to differentiate their product and potentially achieve premium pricing for extended effects. The technology is often applicable when clients are considering the life cycle management of established products.
Medpharm can support clients throughout the development process from initial API characterisation to clinical manufacture. Importantly, Medpharm offers flexibility to deliver the parts of a client's development programme which best fit with their requirements. Fundamentally, Medpharm will propose to clients the optimal program for their current circumstances that maximises the change for achieving the desired outcome and efficiently mitigates the risks associated with the project. Our strategy is aimed at leveraging and expanding the firm's unique capabilities to continue to provide clients with outstanding service, enabling them to deliver outstanding treatments for the ultimate consumer.

Business review
 
With a view to maintaining their standing in the market, Medpharm continued to invest in business development and marketing capabilities. However, revenue declined from £18.7m in 2022 to £11.3m in 2023. The pipeline for future revenue however remains strong. 

Page 1

 
MEDPHARM LIMITED
 

STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Principal risks and uncertainties
 
The principal risks and uncertainties facing the company are discussed below:
Financial risk management
Credit risk
Medpharm is exposed to credit risk from credit sales. It is group policy that the credit risk of customers is assessed and to factor the information from the assessment into future dealings with customers, therefore mitigating the risk. Medpharm also requires significant upfront payments from customers to cover ongoing project costs and operates stringent credit control procedures across all group companies.
Liquidity risk
The company actively manages its finances by reviewing cashflows, performance against budget and the availability of working capital to ensure that it has sufficient available funds for its operations.
Interest rate risk
The company monitors all interest bearing assets and liabilities and their financial impact.
FX risk
The company is exposed to foreign exchange fluctuation risk through expanding activities with overseas customers. The company mitigates these risks by denominating contracts in stable currencies, monitoring foreign exchange movements and planning accordingly.
Market risk
The industry in which the group operate has experienced a sustained period of challenges, including the
reduction of financing available to its customers and potential customers. The impact of this on the business is
mitigated by aggressive management of the group's cost structure to ensure operations sufficient liquidity to
maintain operations.
Operational risk management
Resourcing risk
Medpharm aims to be lean and as responsive to client demands as possible. Managing capacity and throughput have always been key to achieving high profitability levels. However, with increasing success in targeting blue chip clients, managing client agendas and balancing work schedules are even more critical to avoiding lost throughput.
Project risk
There are inherent risks with all research projects, which are compounded by frequent changes in client strategies, which can lead to early terminations of projects which show less favourable results. We aim to mitigate these risks via contract terms and flexible scheduling wherever possible.
Management and staff risk
The business has expanded its senior management team, which helps mitigate the risks inherent in a rapidly growing business and reduce reliance on a few key individuals. Employee engagement initiatives are being put into place to improve staff retention and build a stable knowledge base, which should provide longer term resilience.




 
Page 2

 
MEDPHARM LIMITED
 

STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Health and safety
The company conducts its business in a manner that protects the safety of those involved in its operations. The company strives to prevent all accidents, incidents and occupational illnesses through its Health, Safety, Security & Environment (HSSE) Management System. This is embedded into everyday work processes at all levels of the organisation and addresses all aspects of managing safety and health, as well as security, environmental and social risks at our facilities. The company is committed to continuous efforts to identify and eliminate or management health and safety risks associated with its activities. 

Financial key performance indicators
 
A range of Key Performance Indicators (KPIs) are used to monitor and manage the business and ensure focus is maintained on the key priorities, outlined below:
        
31 December 2023 31 December 2022
Revenue       £11,296,451   £18,676,309
(Loss)/profit before tax     (£6,940,548)   (£5,355,631)
Working capital (net current (liabilities)/assets) (£9,245,902)              (£2,597,532)


This report was approved by the board and signed on its behalf.



T Wahlbrink
Director

Date: 11 April 2025

Page 3

 
MEDPHARM LIMITED
 
 
 
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

The directors present their report and the financial statements for the year ended 31 December 2023.

Directors' responsibilities statement

The directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the directors are required to:


select suitable accounting policies for the Company's financial statements and then apply them consistently;

make judgments and accounting estimates that are reasonable and prudent;

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Results and dividends

The loss for the year, after taxation, amounted to £6,865,187 (2022 - loss £4,936,490).

No dividends were paid during the year. The directors do not recommend payment of a final dividend.

Directors

The directors who served during the year were:

M B Brown (resigned 17 January 2024)
A G Muddle (resigned 17 January 2024)
D J Parker 
T Wahlbrink 
E F Ciolfi (resigned 31 March 2023)

Page 4

 
MEDPHARM LIMITED
 
 
 
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Future developments

In parallel with fee for service for our clients as outlined above, Medpharm is constantly looking for opportunities to develop new formulation and drug delivery technologies which enhance clients' products, provide clinical benefits for patients and meet the increasingly stringent requirements of regulatory authorities.
Medpharm believes that current services can be more broadly deployed to improve the lives of an even wider group of consumers and to do so we need to communicate with a broader market and clearly demonstrate tangible benefits to potential clients, emphasising our top-quality, rapid and low risk development propositions.
Additional investments to expand capacity are in progress and complimentary acquisitions will be sought where significant synergies exist.

Going concern

The financial statements have been prepared assuming the company will continue as a going concern. The going concern assumption contemplates the realisation of assets and satisfaction of liabilities in the normal course of business. However, the industry in which the company operates has experienced a prolonged downturn, which has resulted in many of the company’s customers facing financial challenges. As such, the company experienced a significant decline in turnover in recent years culminating in the generation of an operating loss of £6,945,218 in 2023. In response, in 2024, the wider group undertook multiple refinancing transactions in order to fund its operations. In addition, the group merged with Tergus Pharma Inc., a similarly sized, US-based contract development and manufacturing organization (CDMO) that also focused on topical and transdermal pharmaceuticals. As a result of the merger with Tergus and the expansion opportunities afforded by the combined businesses, the Group required additional funding to continue its operations and finance growth initiatives. 
In April 2025, the group was refinanced by its existing shareholder group. The refinancing included US$11.9 million of new equity financing, US$3.0 million of which was used to reduce the third-party debt obligations of the group. This financing, in combination with additional equity investments made in late 2024 and early 2025, bring the total recent financing efforts of the group to US$18.0 million.  The directors of the group continue to explore other strategies that will help ensure continued operations, including incremental cost reductions, expansion of its offerings to new end-markets and geographies, and the merger or acquisition of other companies in the industry. All such things taken into consideration allows the directors to conclude that, the company shall have the necessary liquidity to conduct normal operations through a date twelve months beyond the date of these financial statements. Accordingly, the financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the company were unable to continue as a going concern.

Qualifying third party indemnity provisions

The company has made qualifying third party indemnity provisions for the benefit of its directors during the year. These provisions remain in force at the reporting date.

Disclosure of information to auditor

Each of the persons who are directors at the time when this Directors' report is approved has confirmed that:
 
so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and

the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Page 5

 
MEDPHARM LIMITED
 
 
 
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Post balance sheet events

The wider Medpharm group has undergone significant restructuring since the balance sheet date, as outlined in note 25 to the financial statements. 

Auditor

The auditor previously traded through the legal entity MacIntyre Hudson LLP. In response to regulatory changes, MacIntyre Hudson LLP ceased to hold an audit registration with engagement transitioning to MHA Audit Services LLP. MHA will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the board and signed on its behalf.
 





T Wahlbrink
Director

Date: 11 April 2025

Page 6

 
MEDPHARM LIMITED
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MEDPHARM LIMITED
 

Opinion


We have audited the financial statements of Medpharm Limited (the 'Company') for the year ended 31 December 2023, which comprise the Statement of comprehensive income, the Statement of financial position, the Statement of changes in equity and the related notes, including a summary of significant accounting policiesThe financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).


In our opinion the financial statements:


give a true and fair view of the state of the Company's affairs as at 31 December 2023 and of its loss for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.


Basis for opinion


We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Conclusions relating to going concern


In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.


Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.


Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.


Page 7

 
MEDPHARM LIMITED
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MEDPHARM LIMITED (CONTINUED)


Other information


The other information comprises the information included in the Annual Report other than the financial statements and our Auditor's report thereon. The directors are responsible for the other information contained within the Annual ReportOur opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.


We have nothing to report in this regard.


Opinion on other matters prescribed by the Companies Act 2006
 

In our opinion, based on the work undertaken in the course of the audit:


the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.


Matters on which we are required to report by exception
 

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic report or the Directors' report.


We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:


adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.


Responsibilities of directors
 

As explained more fully in the Directors' responsibilities statement set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.


In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.


Page 8

 
MEDPHARM LIMITED
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MEDPHARM LIMITED (CONTINUED)


Auditor's responsibilities for the audit of the financial statements
 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.


Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
 
Enquiry of management and those charged with governance around actual and potential litigation claims;
Performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias;
Reviewing minutes of meetings for those changes with governance; and
Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.

 
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.


A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's report.


Use of our report
 

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.


Page 9

 
MEDPHARM LIMITED
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MEDPHARM LIMITED (CONTINUED)





Stephen Poleykett BA (Hons) FCA (Senior statutory auditor)
  
for and on behalf of
MHA
 
London, United Kingdom

11 April 2025
MHA is the trading name of MHA Audit Services LLP, a limited liability partnership in England and Wales
(registered number OC455542).
Page 10

 
MEDPHARM LIMITED
 
 
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2023

As restated
2023
2022
Note
£
£

  

Turnover
 4 
11,296,451
18,676,309

Cost of sales
  
(13,155,706)
(17,613,492)

Gross (loss)/profit
  
(1,859,255)
1,062,817

Administrative expenses
  
(5,097,220)
(6,730,911)

Exceptional administrative expenses
 12 
-
(243,915)

Other operating income
 5 
11,257
555,108

Operating loss
 6 
(6,945,218)
(5,356,901)

Interest receivable and similar income
  
4,670
1,270

Loss before tax
  
(6,940,548)
(5,355,631)

Tax on loss
 11 
75,361
419,141

Loss for the financial year
  
(6,865,187)
(4,936,490)

Other comprehensive income for the year
  

Currency translation differences
  
(37,106)
(778,883)

Other comprehensive income for the year
  
(37,106)
(778,883)

Total comprehensive income for the year
  
(6,902,293)
(5,715,373)

The notes on pages 15 to 30 form part of these financial statements.

Page 11

 
MEDPHARM LIMITED
REGISTERED NUMBER: 03783386

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

As restated
2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 13 
2,786,146
3,040,069

Investments
  
166,778
166,778

  
2,952,924
3,206,847

Current assets
  

Stocks
 15 
50,281
60,642

Debtors: amounts falling due within one year
 16 
4,037,527
5,943,624

Cash at bank and in hand
 17 
576,116
976,583

  
4,663,924
6,980,849

Creditors: amounts falling due within one year
 18 
(13,909,826)
(9,578,381)

Net current liabilities
  
 
 
(9,245,902)
 
 
(2,597,532)

  

Net (liabilities)/assets
  
(6,292,978)
609,315


Capital and reserves
  

Called up share capital 
 19 
10,025
10,025

Share premium account
 20 
73,148
73,148

Capital redemption reserve
 20 
71
71

Share based payment reserve
 20 
-
1,136,120

Profit and loss account
 20 
(6,376,222)
(610,049)

  
(6,292,978)
609,315


The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




T Wahlbrink
Director

Date: 11 April 2025

The notes on pages 15 to 30 form part of these financial statements.

Page 12

 
MEDPHARM LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2023


Called up share capital
Share premium account
Capital redemption reserve
Share based payment reserve
Profit and loss account
Total equity

£
£
£
£
£
£

At 1 January 2023 (as restated)
10,025
73,148
71
1,136,120
(610,049)
609,315


Comprehensive income for the year

Loss for the year

-
-
-
-
(6,865,187)
(6,865,187)

Currency translation differences
-
-
-
-
(37,106)
(37,106)


Other comprehensive income for the year
-
-
-
-
(37,106)
(37,106)


Total comprehensive income for the year
-
-
-
-
(6,902,293)
(6,902,293)

Transfer to/from profit and loss account
-
-
-
(1,136,120)
1,136,120
-


Total transactions with owners
-
-
-
(1,136,120)
1,136,120
-


At 31 December 2023
10,025
73,148
71
-
(6,376,222)
(6,292,978)


The notes on pages 15 to 30 form part of these financial statements.

Page 13

 
MEDPHARM LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2022


Called up share capital
Share premium account
Capital redemption reserve
Share based payment reserve
Profit and loss account
Total equity

£
£
£
£
£
£

At 1 January 2022
10,025
73,148
71
774,367
5,105,324
5,962,935


Comprehensive income for the year

Loss for the year (as restated)

-
-
-
-
(4,936,490)
(4,936,490)

Currency translation differences
-
-
-
-
(778,883)
(778,883)


Other comprehensive income for the year
-
-
-
-
(778,883)
(778,883)


Total comprehensive income for the year
-
-
-
-
(5,715,373)
(5,715,373)


Contributions by and distributions to owners

Share based payment charge
-
-
-
361,753
-
361,753


Total transactions with owners
-
-
-
361,753
-
361,753


At 31 December 2022 (as restated)
10,025
73,148
71
1,136,120
(610,049)
609,315


The notes on pages 15 to 30 form part of these financial statements.

Page 14

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


General information

Medpharm Limited is a private company limited by shares and is registered and incorporated in England and Wales in the United Kingdom. The registered office is Unit 3, Chancellor Court, 50 Occam Road, Surrey Research Park, Guildford, Surrey, GU2 7AB.
The company's principal activities and nature of its operations are disclosed in the Directors' Report.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The financial statements include a prior year adjustment in respect of the figures as at 31 December 2022. The figures for 31 December 2022 have therefore been restated, see note 21.

The following principal accounting policies have been applied:

 
2.2

Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
the requirements of Section 7 Statement of Cash Flows;
the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
the requirements of Section 26 Share-based Payment paragraphs 26.18(b), 26.19 to 26.21 and 26.23;
the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Medpharm Holdco Limited as at 31 December 2023 and these financial statements may be obtained from Companies House, Crown Way, Cardiff, CF14 3UZ.

 
2.3

Exemption from preparing consolidated financial statements

The Company is a parent company that is also a subsidiary included in the consolidated financial statements of a larger group by a parent undertaking established under the law of any part of the United Kingdom and is therefore exempt from the requirement to prepare consolidated financial statements under section 400 of the Companies Act 2006.

Page 15

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.4

Going concern

The financial statements have been prepared assuming the company will continue as a going concern. The going concern assumption contemplates the realisation of assets and satisfaction of liabilities in the normal course of business. However, the industry in which the company operates has experienced a prolonged downturn, which has resulted in many of the company’s customers facing financial challenges. As such, the company experienced a significant decline in turnover in recent years culminating in the generation of an operating loss of £6,945,218 in 2023. In response, in 2024, the wider group undertook multiple refinancing transactions in order to fund its operations. In addition, the group merged with Tergus Pharma Inc., a similarly sized, US-based contract development and manufacturing organization (CDMO) that also focused on topical and transdermal pharmaceuticals. As a result of the merger with Tergus and the expansion opportunities afforded by the combined businesses, the Group required additional funding to continue its operations and finance growth initiatives. 
In April 2025, the group was refinanced by its existing shareholder group. The refinancing included US$11.9 million of new equity financing, US$3.0 million of which was used to reduce the third-party debt obligations of the group. This financing, in combination with additional equity investments made in late 2024 and early 2025, bring the total recent financing efforts of the group to US$18.0 million.  The directors of the group continue to explore other strategies that will help ensure continued operations, including incremental cost reductions, expansion of its offerings to new end-markets and geographies, and the merger or acquisition of other companies in the industry. All such things taken into consideration allows the directors to conclude that, the company shall have the necessary liquidity to conduct normal operations through a date twelve months beyond the date of these financial statements. Accordingly, the financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the company were unable to continue as a going concern.

 
2.5

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP and rounded to the nearest £.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except to the extent that they relate to gains or losses on non-monetary items recognised in other comprehensive income, when the related transaction gain or loss is also recognised in other comprehensive income.

Page 16

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.6

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.7

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.8

Research and development

Research and development expenditure is written off against profits in the year in which it is incurred.
The estimated claim is recognised within other operating income.

 
2.9

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 17

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.10

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.11

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.12

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

 
2.13

Exceptional items

Exceptional items are transactions that fall within the ordinary activities of the Company but are presented separately due to their size or incidence.

 
2.14

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 18

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)


2.14
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives.

Depreciation is provided on the following basis:

Long-term leasehold property
-
5-20% straight line
Plant and machinery
-
10-20% straight line
Fixtures and fittings
-
15% straight line
Office equipment
-
20% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.15

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.16

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. 

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.17

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.18

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.19

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 19

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.20

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Statement of financial position when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

Other financial assets

Other financial assets, which includes investments in equity instruments which are not classified as subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the recognised transaction price. Such assets are subsequently measured at fair value with the changes in fair value being recognised in the profit or loss. Where other financial assets are not publicly traded, hence their fair value cannot be measured reliably, they are measured at cost less impairment.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at each reporting date. 

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.
 

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.
Page 20

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)


2.20
Financial instruments (continued)


Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.


3.


Judgments in applying accounting policies and key sources of estimation uncertainty

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Critical accounting estimates and assumptions
The company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results.
Long-term contracts
Estimates are made in respect of establishing the stage of completion of long-term contracts. In determining the stage of completion, the directors estimate the costs to complete and compare costs incurred as a proportion of total expected costs. Costs relate mainly to contractual hourly staff rates, materials and equipment.
Recoverability of receivables
The company establishes a provision for receivables that are estimates not to be recoverable. When assessing recoverability, the directors consider factors such as the ageing of the receivables, past experience of recoverability, and the credit profile of individual or groups of customers.
Equity-settled share options
In relation to equity-settled remuneration schemes, employee services received, and the corresponding increase in equity, are measured by reference to the fair value of the equity instruments at the date of grant. The fair value of share options is estimated using valuation models, such as Black-Scholes, on the date of grant based on certain assumptions.

Page 21

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

4.


Turnover

Analysis of turnover by country of destination:

2023
2022
£
£

United Kingdom
1,423,230
1,494,105

Rest of Europe
2,032,093
2,054,394

Rest of the world
7,841,128
15,127,810

11,296,451
18,676,309



5.


Other operating income

2023
2022
£
£

Other operating income
11,257
555,108

11,257
555,108



6.


Operating loss

The operating loss is stated after charging:

2023
2022
£
£

Exchange differences
8,429
653,062

Other operating lease rentals
470,973
507,510


7.


Auditor's remuneration

During the year, the company obtained the following services from the company's auditor:


2023
2022
£
£

Fees payable to the company's auditor for the audit of the company's financial statements
100,000
110,000

Page 22

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

8.


Employees

Staff costs, including directors' remuneration, were as follows:


2023
2022
£
£

Wages and salaries
3,624,691
4,440,757

Social security costs
354,948
451,588

Cost of defined contribution scheme
172,059
215,514

4,151,698
5,107,859


The average monthly number of employees, including the directors, during the year was as follows:


        2023
        2022
            No.
            No.







Employees
94
115


9.


Directors' remuneration

2023
2022
£
£

Directors' emoluments
72,002
798,386

72,002
798,386


The highest paid director received remuneration of £72,002 (2022 - £456,880).

The value of the Company's contributions paid to a defined contribution pension scheme in respect of the highest paid director amounted to £NIL (2022 - £NIL).


10.


Interest receivable

2023
2022
£
£


Other interest receivable
4,670
1,270

4,670
1,270

Page 23

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

11.


Taxation


As restated
2023
2022
£
£

Corporation tax


Current tax on profits for the year
(75,361)
-


(75,361)
-


Total current tax
(75,361)
-

Deferred tax


Derecognition of deferred tax asset
-
(419,141)

Total deferred tax
-
(419,141)


Tax on loss
(75,361)
(419,141)

Factors affecting tax charge for the year

The tax assessed for the year is higher than (2022 - higher than) the standard rate of corporation tax in the UK of 23.5% (2022 - 19%). The differences are explained below:

As restated
2023
2022
£
£


Loss on ordinary activities before tax
(6,940,548)
(5,355,631)


Loss on ordinary activities multiplied by standard rate of corporation tax in the UK of 23.5% (2022 - 19%)
(1,631,029)
(1,017,570)

Effects of:


Expenses not deductible for tax purposes, other than goodwill amortisation and impairment
88,541
67,116

Fixed asset timing differences
51,437
(152,918)

Deferred tax adjustments in respect of prior periods
-
(419,141)

Unrelieved tax losses carried forward
1,415,690
1,103,372

Total tax charge for the year
(75,361)
(419,141)

Page 24

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
 
11.Taxation (continued)


Factors that may affect future tax charges

Deferred tax assets have not been recognised in respect of losses of £12,318,792 (2022 - £4,856,025) as
it is not probable that they will be recovered against the reversal of deferred tax liabilities or other future
taxable profits.


12.


Exceptional items

2023
2022
£
£


Aborted sale
-
243,915

-
243,915

During the prior year, progress was made in an agreement to sell the company, incurring costs of £243,915. However, ultimately, the transaction was abandoned.


13.


Tangible fixed assets





Long-term leasehold property
Plant and machinery
Fixtures and fittings
Office equipment
Total

£
£
£
£
£



Cost or valuation


At 1 January 2023
2,111,885
3,319,061
326,365
508,252
6,265,563


Additions
8,155
226,392
9,013
32,027
275,587



At 31 December 2023

2,120,040
3,545,453
335,378
540,279
6,541,150



Depreciation


At 1 January 2023
584,255
2,219,477
167,190
254,572
3,225,494


Charge for the year
134,476
326,336
23,183
45,515
529,510



At 31 December 2023

718,731
2,545,813
190,373
300,087
3,755,004



Net book value



At 31 December 2023
1,401,309
999,640
145,005
240,192
2,786,146



At 31 December 2022
1,527,630
1,099,584
159,175
253,680
3,040,069

Page 25

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

14.


Fixed asset investments





Investments in subsidiary companies
Loans to subsidiaries
Total

£
£
£



Cost or valuation


At 1 January 2023
340
166,438
166,778



At 31 December 2023
340
166,438
166,778





Subsidiary undertaking


The following was a subsidiary undertaking of the Company:

Name

Registered office

Class of shares

Holding

MP Pharma Services Inc.
42222 Emperor Blvd, Suite 320, Durham, NC 27703
Ordinary
100%

The aggregate of the share capital and reserves as at 31 December 2023 and the profit or loss for the year ended on that date for the subsidiary undertaking was as follows:

Name

MP Pharma Services Inc.


15.


Stocks

2023
2022
£
£

Raw materials and consumables
50,281
60,642

50,281
60,642


Page 26

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

16.


Debtors

2023
2022
£
£


Trade debtors
1,355,256
2,511,034

Other debtors
617,152
1,242,556

Prepayments and accrued income
2,065,119
2,190,034

4,037,527
5,943,624



17.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
576,116
976,583

Less: bank overdrafts
(3,566)
-

572,550
976,583



18.


Creditors: Amounts falling due within one year

2023
2022
£
£

Bank overdrafts
3,566
-

Trade creditors
748,372
737,689

Amounts owed to group undertakings
10,735,804
5,597,669

Other taxation and social security
118,438
179,164

Other creditors
189,847
110,166

Accruals and deferred income
2,113,799
2,953,693

13,909,826
9,578,381


Amounts owed to group undertakings are unsecured, payable on demand and interest free.

Page 27

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

19.


Share capital

2023
2022
£
£
Authorised, allotted, called up and fully paid



423,000 (2022 - 423,000) Ordinary shares of £0.01 each
4,230
4,230
408,200 (2022 - 408,200) Ordinary G1 shares of £0.01 each
4,082
4,082
171,300 (2022 - 171,300) Ordinary G2 shares of £0.01 each
1,713
1,713

10,025

10,025

The company's Ordinary shares carry no right to fixed income but carry the right to one vote at general meetings of the company.
The company's Ordinary G1 shares and Ordinary G2 shares carry no right to vote at the general meetings of the company.



20.


Reserves

Share premium account

The share premium account relates to consideration received for shares issued above their nominal value net of transaction costs.

Capital redemption reserve

The capital redemption reserve records the nominal value of shares repurchased by the company.

Share based payment reserve

The share based payment reserve represents the cumulative share based payment expense for the company's share option schemes.

Profit and loss account

The profit and loss account is represented by retained earnings.


21.


Prior year adjustment

The financial statements of Medpharm Limited have been restated to incorporate the impact of an error in the previous year. A deferred tax liability of £567,769 had been recognised in relation to timing differences between capital allowances and depreciation, however the taxable losses of the company as at 31 December 2022 were sufficient to offset against the timing differences, and therefore no deferred tax liability should have been recognised. Deferred tax liabilities have therefore decreased by £567,769 as has the company's tax charge, whilst retained earnings as at 31 December 2022 have increased by the same amount. 

Page 28

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

22.


Pension commitments

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund in the year and amounted to £172,049 (2022 - £215,514). Contributions totalling £24,167 (2022 - £27,142) were payable to the fund at the balance sheet date and are included in creditors.


23.


Commitments under operating leases

At 31 December 2023 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2023
2022
£
£


Not later than 1 year
342,340
313,227

Later than 1 year and not later than 5 years
1,369,360
687,133

Later than 5 years
770,265
-

2,481,965
1,000,360


24.


Related party transactions

The company has taken advantage of the exemptions provided by Section 33 of FRS 102 'Related Party Disclosures' and has not disclosed transactions entered into between two or more members of a group, provided that any subsidiary undertaking which is party to the transactions is wholly owned by a member of that group.

Page 29

 
MEDPHARM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

25.


Post balance sheet events

In January 2024, the parent company of Medpharm Limited was refinanced, issuing 20,767,148 Series A Preferred Shares for £20,767,148 from new investors. As a result of this transaction, the existing shareholders shares were sold or retired. The funding from this equity transaction was used to completely retire the third-party bank debt of the group and provide operating funding to Medpharm Limited.
 
In June 2024, the parent company of Medpharm merged with Tergus Pharma Inc., a similarly sized, US-based contract development and manufacturing organization.  
 
In December 2024, the parent company of Medpharm Limited entered into a US$4,000,000 (approximately £3.1 million) financing transaction with certain existing shareholders.  
 
In March 2025, the parent company of Medpharm Limited entered into a US$2,000,000 (approximately £1.5 million) financing transaction with certain existing shareholders.
In April 2025, the parent company of Medpharm Limited was recapitalised, which included incremental equity financing from certain existing shareholders and a coterminous restructuring of debt obligations assumed in the June 2024 merger with Tergus.  The recapitalization included US$11.9 million of financing from new equity issuances, of which US$3.0 million was used to reduce the company’s outstanding debt.  The lender also agreed to convert 50% of the remaining debt balance into an equity instrument. The remainder of the financing will be used to support continued operations of the Company.


26.


Controlling party

Ampersand 2014 Limited Partnership is the ultimate controlling party.
Medpharm Holdco Limited is the immediate parent, a company registered in the United Kingdom at Unit 3, Chancellor Court 50 Occam Road, Surrey Research Park, Guildford, GU2 7AB. Medpharm Holdco Limited is the smallest and largest group for which consolidated accounts including Medpharm Limited are prepared.
Following the restructuring of the group in June 2024, the ultimate parent of the group is now Montana Holdco LLC, a limited company registered in Delaware in the United States of America.

Page 30